Item 1.01. Entry into a Material Definitive Agreement.

On October 2, 2020, NeuBase Therapeutics, Inc. (the "Company") entered into a Lease Agreement (the "Lease") with 350 Technology Drive Partners, LLC (the "Landlord") for office and laboratory space (the "Leased Premises") located at 350 Technology Drive, Pittsburgh, Pennsylvania (the "Property"). The Leased Premises will serve as the Company's headquarters upon the commencement of the Lease.

The initial term of the Lease commences upon the Landlord's delivery of the Leased Premises in tenant improvement readiness condition (the "Commencement Date"). The initial term of the Lease will extend approximately ten years from the Commencement Date, unless earlier terminated in accordance with the Lease. The Company will have the right to extend the term of the Lease for additional 5-year terms.

Under the Lease, the Company will lease approximately 14,189 square feet at the Property. The Company will pay an escalating base rent over the life of the Lease of approximately $63,000 to $70,000 per month. In addition, the Company will pay its pro rata portion of property expenses and operating expenses for the Property.

The foregoing description of the terms of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, which will be filed with the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2020 or via an amendment to this Current Report on Form 8-K.

The representations, warranties and covenants contained in the Lease were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Lease, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Lease is incorporated herein by reference only to provide investors with information regarding the terms of the Lease, and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company's periodic reports and other filings with the Securities and Exchange Commission.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an


           Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.

© Edgar Online, source Glimpses